|
業務類別
|
-- |
|
業務概覽
|
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK. |
| 公司地址
| 4955 Directors Place, San Diego, CA, USA, 92121 |
| 電話號碼
| +1 858 203-4100 |
| 傳真號碼
| +1 858 203-4028 |
| 公司網頁
| https://www.sorrentotherapeutics.com |
| 員工數量
| 957 |
| Dr. Henry Ji,PhD |
Chairman of the Board, President and Chief Executive Officer |
-- |
16/03/2023 |
|
|
| Ms. Tammy Reilly |
Independent Director |
16/03/2023 |
| Mr. Jaisim Shah |
Director |
16/03/2023 |
| Mr. David Jakob Lemus |
Independent Director |
16/03/2023 |
| Mr. Dorman Followwill |
Lead Independent Director |
16/03/2023 |
| Dr. Henry Ji,PhD |
Chairman of the Board, President and Chief Executive Officer |
16/03/2023 |
| Dr. Kim D. Janda, PhD |
Director |
16/03/2023 |
| Dr. Yue Alexander Wu, PhD |
Independent Director |
16/03/2023 |
|
|
|
|
